RxDoctor Payments Data

Mouna Bacha, MD

Internal Medicine · Clearwater, FLNPI 1568439941

Payments from drug & device makers

$1,528in general payments, 2019–2025

Across 87 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$265
  • Johnson & Johnson$237
  • Amarin Pharma, Inc.$179
  • Boehringer Ingelheim$170
  • AstraZeneca$155
  • Pfizer$116
  • plus $408 from 11 others

What the payments were for

  • Food & beverage$1,528100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,528 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$630,121
Medicare patients
984
Services billed
6,703

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban506$189,375
XareltoRivaroxaban189$60,374
JanuviaSitagliptin Phosphate50$27,087
EntrestoSacubitril/Valsartan42$24,449
JardianceEmpagliflozin47$22,720
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$21,546
FarxigaDapagliflozin Propanediol45$19,314
LinzessLinaclotide22$16,083
MyrbetriqMirabegron50$15,940
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$13,209
Breo ElliptaFluticasone/Vilanterol40$12,907
TrulicityDulaglutide11$11,330
CreonLipase/Protease/Amylase11$10,743
ArexvyRsvpref3 Antigen/As01e/Pf32$10,216
ProcritEpoetin Alfa21$9,441

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Retacrit$116$193,261533 claims
Johnson & JohnsonXarelto, Procrit$237$69,815210 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Anoro Ellipta, Incruse Ellipta$65$55,561130 claims
AbbVieLinzess, Creon, Restasis$42$35,75347 claims
AstraZenecaFarxiga, Breztri Aerosphere$155$32,52359 claims
Boehringer IngelheimJardiance, Spiriva Respimat$170$29,15662 claims
MerckJanuvia$12$27,08750 claims
NovartisEntresto$265$24,44942 claims
Astellas Pharma US IncMyrbetriq$41$15,94050 claims
Lilly USA, LLCTrulicity$103$11,33011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →